Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 trial of Solriamfetol in Subjects With Major Depressive Disorder (MDD) patients with Excessive Daytime Sleepiness (EDS)

Next Previous
Search
Trial Profile

A Phase 3 trial of Solriamfetol in Subjects With Major Depressive Disorder (MDD) patients with Excessive Daytime Sleepiness (EDS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solriamfetol (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use

Most Recent Events

  • 04 Apr 2025 New trial record
  • 01 Apr 2025 According to Axsome Therapeutics media release, based on the results in the EDS subgroup of NCT06360419 study, company plans to initiate this trial in MDD patients with EDS in 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top